Pioneering a health care innovation ecosystem to better serve patients
NEWDIGS Initiative at MIT leads multi-stakeholder collaboration to design and pilot a sustainable, patient-centered innovation ecosystem for a target disease.
NEWDIGS Initiative at MIT leads multi-stakeholder collaboration to design and pilot a sustainable, patient-centered innovation ecosystem for a target disease.
New strategy could enable existing drugs to kill bacteria that cause chronic infections.
Industry leaders, patient advocates, and policymakers collaborate to make groundbreaking new therapies economically sustainable.
Studies by Richard Wurtman have led to development of nutrient mix shown to slow cognitive impairment in early stages of the disease.
Microparticles created by new 3-D fabrication method could release drugs or vaccines long after injection.
MIT affiliates recognized for their innovative approaches to energy storage and drug discovery.
Study finds bacterial response to drugs varies in different environments.
In study that may guide drug design, researchers find organelles encounter varying levels of resistance.
Honor recognizes bioengineer’s advance of analytical techniques for characterization of biopharmaceuticals.
Entrepreneurs, researchers, and industry experts build connections at workshop.
Termeer built Genzyme from a startup into a biotech powerhouse, while becoming an innovator in rare-disease drug development.
Differences in chromosome number may underlie variation among genetically identical individuals.
Beckman Foundation grant helps secure cryo-electron microscopy at MIT.nano facility.
Researchers program RNA nanoparticles that could protect against the virus.
Automated manufacturing could make it easier to develop and test new peptide drugs.